ZA200706238B - Prevention and treatment of thromboembolic disorders - Google Patents

Prevention and treatment of thromboembolic disorders

Info

Publication number
ZA200706238B
ZA200706238B ZA200706238A ZA200706238A ZA200706238B ZA 200706238 B ZA200706238 B ZA 200706238B ZA 200706238 A ZA200706238 A ZA 200706238A ZA 200706238 A ZA200706238 A ZA 200706238A ZA 200706238 B ZA200706238 B ZA 200706238B
Authority
ZA
South Africa
Prior art keywords
prevention
treatment
thromboembolic disorders
thromboembolic
disorders
Prior art date
Application number
ZA200706238A
Other languages
English (en)
Inventor
Misselwitz Frank
Kubitza Dagmar
Park Son-Mi
Wehling Klaus
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200706238(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of ZA200706238B publication Critical patent/ZA200706238B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA200706238A 2005-01-31 2007-07-27 Prevention and treatment of thromboembolic disorders ZA200706238B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05001893A EP1685841A1 (en) 2005-01-31 2005-01-31 Prevention and treatment of thromboembolic disorders

Publications (1)

Publication Number Publication Date
ZA200706238B true ZA200706238B (en) 2008-11-26

Family

ID=34933512

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200706238A ZA200706238B (en) 2005-01-31 2007-07-27 Prevention and treatment of thromboembolic disorders

Country Status (27)

Country Link
US (1) US9539218B2 (hr)
EP (2) EP1685841A1 (hr)
JP (1) JP2008528527A (hr)
KR (1) KR20070107009A (hr)
CN (1) CN101111236A (hr)
AR (2) AR052565A1 (hr)
AU (1) AU2006208613B2 (hr)
BR (1) BRPI0606760A2 (hr)
CA (1) CA2596145A1 (hr)
CY (1) CY1116494T1 (hr)
DK (1) DK1845961T3 (hr)
ES (1) ES2542335T3 (hr)
HR (1) HRP20150764T1 (hr)
HU (1) HUE025705T4 (hr)
IL (1) IL184585A0 (hr)
MA (1) MA29236B1 (hr)
MX (1) MX2007009100A (hr)
NO (1) NO344278B1 (hr)
NZ (1) NZ556765A (hr)
PL (1) PL1845961T3 (hr)
PT (1) PT1845961E (hr)
SG (1) SG159505A1 (hr)
SI (1) SI1845961T1 (hr)
TW (1) TWI377945B (hr)
UA (1) UA91355C2 (hr)
WO (1) WO2006079474A1 (hr)
ZA (1) ZA200706238B (hr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
CA2823159C (en) 2005-10-04 2014-10-21 Bayer Intellectual Property Gmbh Polymorphic form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
US7816355B1 (en) 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
DK2442791T3 (da) 2009-06-16 2020-03-02 Pfizer Former til dosering af apixaban
EP3378854B1 (en) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
EP2538360A1 (en) * 2011-06-16 2012-12-26 Koninklijke Philips Electronics N.V. Method of predicting a blood dilution risk value
WO2015028919A1 (en) * 2013-08-29 2015-03-05 Daiichi Sankyo Company, Limited Agent for the treatment and prevention of cancer
MX2017016530A (es) 2015-06-22 2018-03-12 Arena Pharm Inc Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
EP3829469A4 (en) * 2018-07-30 2022-04-27 Diffusion Pharmaceuticals LLC DIFFUSION ENHANCING COMPOUNDS AND THEIR USE IN THROMBECTOMY AND EMBOLICTOMY AND OTHER VASCULAR DISEASE PROCEDURES

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2811555A (en) 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
HU190072B (en) 1983-03-11 1986-08-28 Biogal Gyogyszergyar,Hu Process for production of medical preparatives with sinergetic influence
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
ES8506659A1 (es) 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
US4977173A (en) 1987-10-21 1990-12-11 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
ES2059467T3 (es) 1987-10-21 1994-11-16 Du Pont Merck Pharma Derivados de aminometil-oxooxazolidinil-etenilbenceno utiles como agentes antibacterianos.
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
DK0610265T3 (da) 1991-11-01 1997-06-09 Upjohn Co Substituerede aryl- og heteroarylphenyloxazolidioner, som kan anvendes som antibakterielle midler
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5349045A (en) 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
EP0623615B1 (de) 1993-05-01 1999-06-30 MERCK PATENT GmbH Substituierte 1-Phenyl-oxazolidin-2-on Derivate, deren Herstellung und deren Verwendung als Adhäsionsrezeptor-Antagonisten
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
ATE205205T1 (de) 1995-02-03 2001-09-15 Upjohn Co Durch hetero-aromatische ring substituierte phenyloxazolidinone als antimikrobielles mittel
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
US5798375A (en) 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
DE19524765A1 (de) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
KR100463772B1 (ko) 1995-09-01 2005-11-09 파마시아 앤드 업존 캄파니 엘엘씨 4내지8원헤테로사이클릭환에탄소-탄소결합을갖는페닐옥사졸리디논
ATE257829T1 (de) 1995-09-15 2004-01-15 Upjohn Co Aminoaryl oxazolidinone n-oxide
DE19601264A1 (de) 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
GB9614238D0 (en) 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
DK0930076T3 (da) 1996-07-15 2005-01-31 Sankyo Co Farmaceutiske præparater omfattende CS-866 og insulinresistensforbedrende midler og deres anvendelse i behandlingen af arteriosclerose og xanthom
US5935724A (en) 1997-04-04 1999-08-10 Wilson Greatbatch Ltd. Electrochemical cell having multiplate electrodes with differing discharge rate regions
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
JP2002501530A (ja) 1997-05-30 2002-01-15 ファルマシア・アンド・アップジョン・カンパニー チオカルボニル官能基を有するオキサゾリジノン抗菌剤
NZ502253A (en) 1997-07-11 2001-06-29 Upjohn Co Thiadiazolyl and oxadiazolyl phenyl oxazolidinone derivatives which are antibacterial agents
DE19730847A1 (de) 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
SK284577B6 (sk) 1997-11-12 2005-07-01 Pharmacia & Upjohn Company Deriváty oxazolidinónu, ich použitie a farmaceutické kompozície
US6083967A (en) 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
WO1999037630A1 (en) 1998-01-23 1999-07-29 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
IL137517A0 (en) 1998-01-27 2001-07-24 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors
DE19805117A1 (de) 1998-02-09 1999-08-12 Bayer Ag Neue Oxazolidinone mit azolhaltigen Tricyclen
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
DE69902526T2 (de) 1998-05-18 2003-04-03 Pharmacia & Upjohn Co., Kalamazoo Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
PE20010851A1 (es) 1999-12-14 2001-08-17 Upjohn Co Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
CN1221548C (zh) 1999-12-21 2005-10-05 法玛西雅厄普约翰美国公司 含有砜亚氨基官能团的噁唑烷酮
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
WO2001047949A1 (fr) 1999-12-28 2001-07-05 Ajinomoto Co., Inc. Cristaux de derives d'aspartame
KR100415318B1 (ko) 2000-09-23 2004-01-16 탁승호 레이저를 이용한 수평 및 수직선 지시계
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de) 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10115945A1 (de) 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de) 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10134481A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10152460A1 (de) 2001-10-24 2003-05-08 Bayer Ag Stents
DE10238113A1 (de) 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
CA2823159C (en) 2005-10-04 2014-10-21 Bayer Intellectual Property Gmbh Polymorphic form of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
DE102006034916A1 (de) 2006-07-28 2008-01-31 Bayer Healthcare Ag Beschichtung künstlicher Oberflächen von medizinischen Hilfsmitteln und Geräten sowie Reinigung und/oder Vorbehandlung von Kathetern und anderen medizinischen Hilfsmitteln und Geräten
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone

Also Published As

Publication number Publication date
NZ556765A (en) 2010-11-26
CN101111236A (zh) 2008-01-23
AU2006208613A1 (en) 2006-08-03
BRPI0606760A2 (pt) 2009-07-14
PT1845961E (pt) 2015-08-31
WO2006079474A1 (en) 2006-08-03
DK1845961T3 (en) 2015-07-20
HUE025705T2 (en) 2016-04-28
NO344278B1 (no) 2019-10-28
TW200640441A (en) 2006-12-01
US9539218B2 (en) 2017-01-10
MX2007009100A (es) 2007-09-13
SI1845961T1 (sl) 2015-08-31
KR20070107009A (ko) 2007-11-06
US20090004265A1 (en) 2009-01-01
EP1845961A1 (en) 2007-10-24
PL1845961T3 (pl) 2015-09-30
IL184585A0 (en) 2008-12-29
HRP20150764T1 (hr) 2015-08-28
NO20074356L (no) 2007-08-27
AR110413A2 (es) 2019-03-27
CA2596145A1 (en) 2006-08-03
ES2542335T3 (es) 2015-08-04
EP1845961B1 (en) 2015-04-22
CY1116494T1 (el) 2017-03-15
UA91355C2 (ru) 2010-07-26
SG159505A1 (en) 2010-03-30
TWI377945B (en) 2012-12-01
AR052565A1 (es) 2007-03-21
JP2008528527A (ja) 2008-07-31
EP1685841A1 (en) 2006-08-02
HUE025705T4 (hu) 2023-02-28
MA29236B1 (fr) 2008-02-01
AU2006208613B2 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
ZA200706238B (en) Prevention and treatment of thromboembolic disorders
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
EP1853295A4 (en) METHOD AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISEASES
EP1940441A4 (en) COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
IL177772A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
SI2444079T1 (sl) Sestavki in postopki za zdravljenje očesnih motenj
EP1865972A4 (en) TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS
PL1981516T3 (pl) Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom
IL190745A0 (en) Microangiopathy treatment and prevention
EP1910829A4 (en) PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
EP1996218A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
IL191537A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
GB0600948D0 (en) Prevention/Treatment Of Ichthyosis Vulgaris, Atopy And Other Disorders
IL187405A0 (en) Methods and compositions for the treatment of pain
EP1898921A4 (en) COMPOSITIONS AND METHODS FOR TREATING SLEEP DISORDERS
ZA200805108B (en) Treatment of neurodegenerative disorders
ZA200802270B (en) Treatment of neurodegenerative disorders
GB0604826D0 (en) The treatment of inflammatory disorders and pain
GB0504657D0 (en) Compositions and methods of treatment
GB0604822D0 (en) The treatment of inflammatory disorders and pain
ZA200710476B (en) Methods and compositions for the treatment of pain
GB0513413D0 (en) The treatment of inflammatory disorders and pain
ZA200805859B (en) Methods and compositions for the treatment of gastriontestinal disorders